Anatomical navigation to guide catheter ablation for atrial fibrillation and flutter
Official title: Anatomical Navigation for Guided Electrophysiology in AFL and AFib
Run by LUMA Vision Ltd. · NCT07210151 · Data updated 2026-11-12
This trial will test whether the VERAFEYE Anatomical Guidance System helps doctors guide catheter ablation in adults with atrial fibrillation or atrial flutter.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | LUMA Vision Ltd. Industry-sponsored |
| Locations | 4 sites (Split and 3 other locations) |
| Status | Recruiting |
| Started | January 29, 2026 |
| Main results expected | December 16, 2026 |
| Study ends | December 16, 2026 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07210151 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age 18+) who are scheduled to undergo catheter ablation for atrial flutter or atrial fibrillation and who can provide informed consent and complete study assessments.
✕Probably not a fit
Patients for whom placement of the VERAFEYE imaging catheter is technically not feasible, pregnant women, or those with unresolved adverse events from prior procedures are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults scheduled for catheter ablation for atrial flutter, paroxysmal AF, or persistent AF will undergo their planned procedure using the commercial VERAFEYE Anatomical Guidance System. Clinical teams will use the device during mapping and ablation while study staff collect procedural data on how the system is used and immediate procedural outcomes. Data collected will include technical feasibility of catheter placement, acute procedural success metrics, and any procedure-related adverse events. Results will be used to inform refinement and further development of the VERAFEYE system.
Why it matters
Potential benefit: If successful, the system could make mapping and ablation more accurate and efficient, potentially shortening procedures and improving acute success rates.
How similar studies have gone: Other anatomical mapping and intracardiac imaging systems have demonstrated benefit in guiding ablation and reducing fluoroscopy exposure, though VERAFEYE itself is being further characterized in this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * IC1: Subject is at least 18 years of age at the time of consent * IC2: Subject is scheduled to undergo a catheter-ablation procedure to treat AFL/AF (\*according to current international and local guidelines and per physician discretion) * IC3: Subject is able to understand and willing to provide written informed consent * IC4: Subject is able and willing to complete all study assessments associated with this clinical study at an approved clinical study site Exclusion Criteria: * EC1: Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion * EC2: Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure) * EC3: Unrecovered/unresolved Adverse Events from any previous invasive procedure * EC4: Any planned surgical or endovascular intervention within 30 days before or after the ablation procedure. * EC5: Life expectancy less than 12 months * EC6: Current LA thrombus Note: Screening for LA thrombus is required to be performed within 48 hours prior to or during the index procedure. Method of screening per physician discretion. If an atrial thrombus is observed prior to or during the planned index procedure, the index procedure will not begin or will be terminated before accessing the left atrium, and no ablation will be performed. The index procedure for this subject may be rescheduled to be performed within 30 days post ICF signature, provided that the thrombus is no longer present.
Where it's running
-
Klinicki Bolnicki Centar (KBC)
Split, Croatia Recruiting -
Na Homolce Hospital
Prague, Czechia Recruiting -
Ikem
Prague, Czechia Not yet recruiting -
Vilnius University Hospital Santaros klinikos
Vilnius, Lithuania Not yet recruiting
Study contacts
- Study coordinator: Alisa Komleva
- Email: alisa.komleva@lumavision.com
- Phone: 0894352047
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using the VERAFEYE imaging and navigation system to guide catheter ablation for atrial arrhythmias
This study will try the VERAFEYE imaging and guidance system during catheter ablation in adults with atrial flutter or atrial fibrillation to see if it integrates well with standard procedures.
-
Evaluating Atrial Fibrosis as a Predictor for Post-operative Atrial Fibrillation in Cardiac Surgery Patients
This study is trying to see if the amount of atrial fibrosis in patients can help predict if they will have heart rhythm problems after heart surgery.
-
Volta AI software in real-world AF ablation
A real-world observational study will test the latest Volta AF-Xplorer II AI software during atrial fibrillation ablation to see how safe and effective it is over 24 months.
-
HeartBeam ECG Registry: See How Heartbeat Patterns Look Across People
This registry tests HeartBeam ECG recordings in real-world patients to build a de-identified database for research.
-
AV node ablation with left bundle branch area pacing versus right ventricular pacing for atrial fibrillation with preserved heart function
This test checks whether left bundle branch area (LBBA) pacing instead of right ventricular (RV) pacing after AV node ablation better preserves heart function in adults with symptomatic atrial fibrillation and normal ejection fraction.
-
Monitoring heart rhythm after noncardiac surgery
This study is testing if wearing a portable heart monitor for up to 14 days after noncardiac surgery can help find heart rhythm problems that are often missed, to improve care for patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.